tamoxifen citrate

(redirected from Soltamox)

tamoxifen citrate

Apo-Tamox, Gen-Tamoxifen, Nolvadex, Nolvadex-D, Novo-Tamoxifen, PMS-Tamoxifen, Soltamox, Tamofen

Pharmacologic class: Nonsteroidal antiestrogen

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Box Warning

For women with ductal carcinoma in situ or high risk of breast cancer, serious and life-threatening events associated with drug use in riskreduction setting include stroke, pulmonary embolism, and uterine cancer. Some of these events were fatal. Discuss potential benefits versus potential risks of these events with these patients. In women already diagnosed with breast cancer, drug's benefits outweigh risks.


Competes with estrogen receptors in tumor cells for binding to target tissues (such as breast); reduces DNA synthesis and estrogen response


Oral solution: 10 mg/5 ml

Tablets: 10 mg, 20 mg

Tablets (enteric-coated): 20 mg

Indications and dosages

Adjunctive treatment of breast cancer

Adults: 20 to 40 mg P.O. daily for 5 years. Daily dosages of 20 mg may be taken as a single dose; daily dosages above 20 mg should be divided and taken b.i.d. (morning and evening).

To reduce breast cancer incidence in high-risk women; treatment of ductal carcinoma in situ

Adults: 20 mg P.O. daily for 5 years

Off-label uses

• Mastalgia

• Ovulation stimulation


• Hypersensitivity to drug

• Concurrent warfarin use

• Women with a history of deep-vein thrombosis or pulmonary embolism

• Pregnancy or breastfeeding


Use cautiously in:

• decreased bone marrow reserve, leukopenia, thrombocytopenia, cataracts, hyperlipidemia

• females of childbearing age.


• Don't break or crush enteric-coated tablets.

• Know that drug is indicated for reducing breast cancer risk only in high-risk women, defined as those older than age 35 who have at least a 1.67% chance of developing breast cancer over 5 years.

Adverse reactions

CNS: confusion, depression, headache, weakness, fatigue, light-headedness

CV: chest pain, deep-vein thrombosis

EENT: blurred vision, ocular lesion, retinopathy, corneal opacity

GI: nausea, vomiting, abdominal cramps, anorexia

GU: vaginal bleeding, discharge, or dryness; irregular menses; amenorrhea; oligomenorrhea; ovarian cyst; pruritus vulvae; endometrial or uterine cancer

Hematologic: leukopenia, thrombocytopenia

Metabolic: hypercalcemia, fluid retention

Musculoskeletal: bone pain

Respiratory: cough, pulmonary embolism

Skin: skin changes, hair thinning or partial hair loss

Other: altered taste, weight loss, tumor flare, tumor pain, hot flashes, edema


Drug-drug. Aminoglutethimide, estrogens: decreased tamoxifen effects

Antineoplastics: increased risk of thromboembolic events

Bromocriptine: increased tamoxifen blood level

Warfarin: increased anticoagulant effect

Drug-diagnostic tests. Aspartate aminotransferase, bilirubin, calcium, creatinine, hepatic enzymes: increased levels

Platelets, white blood cells: decreased counts

Patient monitoring

• Monitor lipid panel, calcium level, mammography results, and gynecologic exam results.

Watch for signs and symptoms of thromboembolic events, including cerebrovascular accident and pulmonary embolism.

• Monitor menstrual cycle pattern for changes that may signal endometrial or uterine cancer.

Patient teaching

• Tell patient to swallow enteric-coated tablets whole without breaking or crushing.

Instruct patient to immediately report leg or calf pain, swelling, or tenderness; unexpected shortness of breath; sudden chest pain; coughing up blood; new breast lumps; vaginal bleeding; menstrual irregularities; changes in vaginal discharge; pelvic pain or pressure; and vision changes.

• Inform patient that increase in bone or tumor pain usually means drug will be effective. Advise her to discuss pain management with prescriber.

• Stress importance of undergoing regular blood tests, mammograms, and gynecologic exams to identify early signs of serious adverse reactions.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

ta·mox·i·fen cit·rate

(tă-mok'sĭ-fen sit'rāt),
A synthetic nonsteroidal estrogen antagonist used in the prevention and treatment of breast cancer.

Tamoxifen belongs to a class of synthetic agents known as selective estrogen receptor modulators (SERMs). By competing with naturally occurring estrogen for binding sites on tissue cells, tamoxifen inhibits the stimulant effect of estrogen on breast cancers. Tumors that have been shown by biochemical assay to be rich in estrogen receptors are most likely to respond to treatment. Since 1985, tamoxifen has been used to delay or prevent relapse in patients who have undergone surgery or irradiation for breast cancer. The drug has been found effective in reducing the risk of cancer recurrence or disease progression in women with or without axillary node metastasis. In women with extensive disease, tamoxifen therapy has been as effective as oophorectomy in retarding progression. Clinical trials of tamoxifen as a preventive agent in women at high risk of breast cancer have yielded conflicting results; current opinion is against using tamoxifen in women at low or normal risk of breast cancer because of side effects. Genomic analysis of healthy women who developed breast cancer while taking tamoxifen showed that tamoxifen reduced breast cancer incidence in women with the BRCA2 mutation, but not in those with the BRCA1 mutation. Women taking tamoxifen are at increased risk of endometrial carcinoma, stroke, deep venous thrombosis, pulmonary embolism, and cataracts. The danger of these adverse consequences is greatest in women older than 50. Long-term use of the drug is associated with recurrent vaginal candidosis. It is contraindicated during pregnancy because of the risk of fetal harm.

Farlex Partner Medical Dictionary © Farlex 2012

tamoxifen citrate

An antiestrogenic drug used in treating and preventing breast cancer.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
The medications include tamoxifen (Nolvadex, Soltamox) and the aromatase inhibitors anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara).
DARA holds exclusive US marketing rights to Gelclair oral rinse gel, Oravig (miconazole) buccal tablets and Soltamox (tamoxifen citrate oral liquid solution).
CAPTURE is a project of DARA BioSciences, which markets the only Food and Drug Administration-approved liquid tamoxifen formulation (Soltamox).
As with other versions of tamoxifen, the SOLTAMOX product label also includes a black box warning with information on the potential risk of adverse events.
It was reported on Friday that the contract has been signed for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis, and Soltamox (tamoxifen citrate) oral liquid solution, to be accessible to RainTree's Nationwide Oncology Membership.
She said that the new solution, soltamox (Cytogen) is now just showing up on pharmacy shelves.
US-based oncology company DARA BioSciences Inc (NasdaqCM:DARA) reported on Thursday the execution of a pharmacy supply agreement for Gelclair and Soltamox with RainTree Oncology Services.
According to the agreement and a shared sales force agreement with Mission, in addition to promoting Dara's products Soltamox (tamoxifen citrate), Gelclair and Bionect, the Alamo sales team will also carry three Mission Pharmacal products: Ferralet 90 (for anemia), BINOSTO (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral (for chemotherapy/radiation therapy-induced dry mouth).
Net proceeds will be used by DARA BioSciences Inc to fund expenses related to the commercialisation of its complementary portfolio of oncology and oncology supportive care pharmaceutical products, including expenses for the commercial activities related to Soltamox, Gelclair and Bionect and for working capital, business development and other general corporate purposes.
M2 PHARMA-August 17, 2012-DARA BioSciences partners with Seyer Pharmatec Inc for Soltamox's sale in the Puerto Rico market(C)2012 M2 COMMUNICATIONS
According to the company's CEO Dr David J Drutz, the financing will provide additional capital for the commercial activities related to Soltamox, its FDA-approved treatment for breast cancer, for Gelclair, its FDA-cleared product for the treatment of oral mucositis, for general corporate purposes and for additional financing in 2013.